Continuing Education Information
For those seeking continuing education credits for the Conference, the process will be done completely online this year.
The TCE Online system will be available to register, complete session evaluations, and print your Continuing Education certificate(s) for the 2009 National HIV Prevention Conference through September 25, 2009.
You are welcome to go online to register for CE and to select your sessions beginning Monday, August 24, 2009. To do so, please go to the CDC Training and Continuing Education Online at http://www2a.cdc.gov/tceonline.
If you have registered for Continuing Education for previous conferences you will need to use that login and password. If you can't remember your login ID or password please call 1-(800)-41-TRAIN or email ce@cdc.gov between 8AM - 4PM.
- If you have not registered as a CE participant, click on "New Participant" to create a participant profile.
- When you receive your reset password by email, log in as a "Participant" and change the password.
- At "Participant Services", click on Search and Register. Click on the link CDC Courses under the Online Search box on the right side and enter the code EV1408.
- Click on the title of your course, select the type of credit you wish to receive at the bottom, and click "Submit".
- Verify the demographic information and click "Submit" at the bottom.
- Complete the overall conference evaluation and session evaluations.
- At "Participant Services", click on "Certificates and Transcripts" and print your continuing education certificate.
FINANCIAL DISCLOSURES
For Vested or Financial Interest(s), Relationship(s), or Commercial Support
CDC, our planners, and our presenters wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the exception of:
- Dr. Donna Futterman and she wishes to disclose an Educational Grant (Gilead Sciences) and a Research Grant (Orasure Technologies).
- Dr. Frederick Altice and he wishes to disclose a honorarium (Speakers Bureau - BMS, Roche and Merck) and a Research Grant (BI, Gilead).
- Sebastian Zepeda and he wishes to disclose an honorarium (Community Speaker - Gilead, BMS, GSK)
Unlabeled Use of Commercial Product(s) or Product(s) for Investigational Use
Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of:
- Sarah Bodach's discussion - A portion of cases ascertained as acutely infected were found via pooled HIV polymerase chain reaction (PCR) among individuals who tested HIV Ab-negative. This use of PCR has not been approved by the FDA; however, a validation study was first completed and submitted for approval. The protocol and study were approved by the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP). Please refer to internet reference below for additional information.NGI: NY state approves use of NGI HIV RNA test in pooled plasma from clinical patients for diagnostic purposes [Internet] Albany, NY: New York State Department of Health; 2007 May 7. Available from: http://www.ngi.com/company/downloads/NY_Approval_for_HIV_clinical.pdf
- Kevin Cranston's discussion on the use of antiretrovirals for post-exposure prophylaxis. This is currently in clinical trial (investigational use) and no labelling indication is being sought so, if proven effective in trials, will be an unlabelled use. This has been discussed with FDA and is not counter to their guidance.
- Dr. Paula Frew's discussion on the study relating to a clinical trial of the non-nucleoside reverse transcriptase inhibitor (NNRTI) investigational "UC-781" microbicide product originally developed by Biosyn and subsequently managed by Conrad. Participants in this acceptability study included trial participants and their partners who reported on experience with the investigational product. This study does not examine any safety endpoint outcomes from that clinical trial.
- Jennifer Kates' discussion on the use of antiretrovirals for post-exposure prophylaxis. This is currently in clinical trial (investigational use) and no labelling indication is being sought so, if proven effective in trials, will be an unlabelled use. This has been discussed with FDA and is not counter to their guidance.
- Dr. Dawn Smith's discussion on the use of antiretrovirals for post-exposure prophylaxis. This is currently in clinical trial (investigational use) and no labelling indication is being sought so, if proven effective in trials, will be an unlabelled use. This has been discussed with FDA and is not counter to their guidance.
- Dr. Joanne Stekler's discussion which will likely include results of the study of different HIV antibody tests, antibody/antigen combination assays, and HIV NAAT, some of which are not currently licensed for use in the United States and some of which were used (e.g. retesting of frozen specimens) in a manner other than their FDA-approvals.
- Dr. Lucia Torian's discussion on the use of antiretrovirals for post-exposure prophylaxis. This is currently in clinical trial (investigational use) and no labelling indication is being sought so, if proven effective in trials, will be an unlabelled use. This has been discussed with FDA and is not counter to their guidance.
Commercial Support
There is no commercial support for this activity.
CONTINUING EDUCATION
Continuing Medical Education (CME)
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH). The Centers for Disease Control and Prevention is accredited by the ACCME to provide continuing medical education for physicians.
The Centers for Disease Control and Prevention designates this educational activity for a maximum of 10.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education (CNE)
The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity provides 10.5 contact hours.
Continuing Education Contact Hours (CECH) in Health Education
The Centers for Disease Control and Prevention is a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is a designated event for the CHES to receive 10.5 Category I Contact Hours in health education. CDC provider number GA0082.
Continuing Education Units (CEU)
The CDC has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102. The CDC is authorized by IACET to offer 1.4 IACET CEU's for this program.
|
